Argus Research Maintains Buy on DexCom, Raises Price Target to $96

Benzinga Newsdesk www.benzinga.com Positive 70.8%

Neg 0% Neu 0% Pos 70.8%

Argus Research analyst Steve Silver maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price target from $86 to $96.